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Abstract
Background: The purpose of this study was to investigate the diagnostic value of 3.0-T 1H magnetic resonance
spectroscopy (1H MRS) in primary malignant hepatic tumors and to compare the effects of 1H MRS on the diagnostic
accuracy of liver-occupying lesions between junior and experienced radiologists.
Methods: This study included 50 healthy volunteers and 40 consecutive patients (50 lesions). Informed consent was
obtained from each subject. Images were obtained on clinical whole-body 3.0-T MR system. Point -Resolved Spectroscopy
was used to obtain the spectroscopy image. All conventional images were reviewed blindly by junior radiologist and
experienced radiologist, respectively. The choline-containing compounds peak area (CCC-A) was measured with SAGE
software, and the choline-containing compound ratio (ΔCCC) was calculated. The efficacy of CCC-A and ΔCCC in the
diagnosis of primary malignant hepatic tumors was determined by plotting receiver operating characteristic (ROC) curves.
We also compared the effects of MRS on the diagnostic accuracy of liver-occupying lesions with junior and experienced
radiologist.
Results: A significant increase in mean CCC-A was observed in malignant tumors compared with benign tumors.
The ROC curve showed ΔCCC had a high discriminatory ability in diagnosing primary malignant hepatic tumors
with a sensitivity and specificity of 94.3 and 93.3 %, respectively. The ΔCCC area under the curve (AUC) was 0.97
that was larger than that of both junior and experienced radiologist, while the significantly statistical difference
was only obtained between ΔCCC and junior radiologist (P = 0.01).
Conclusion: 1H MRS with ΔCCC demonstrates good efficacy in diagnosing primary malignant hepatic tumors.
The technique improves the accuracy of diagnosing liver-occupying lesions, particularly for junior radiologists.
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Background
Malignant hepatic tumors, including primary liver cancer
and metastatic tumors, are common worldwide. Primary
liver cancer is the fifth most common malignancy in men
and the eighth in women. In a 2008 survey, it was re-
ported that there were 748,000 new cases of liver cancer
diagnosed worldwide, in that year alone, with an estimated
695,000 reported deaths in the same period by the World
Health Organization [1]. Moreover, the liver is the second
most common site for the metastatic spread of cancer. Al-
though progress in non-invasive imaging modalities such
as ultrasound (US), computed tomography (CT) and mag-
netic resonance imaging (MRI) has improved the early
detection and localization of malignant hepatic tumors,
differential diagnosis, such as differentiating malignant
from cirrhosis-related borderline lesions, still remains dif-
ficult, particularly for the junior radiologist. Biopsy is the
current definitive clinical method for diagnosing dilem-
matic liver lesions. However, in view of the invasiveness,
costs, possible complications and sample variability of
biopsy, the establishment of a simple and specific strategy
to diagnose dilemmatic liver lesions are important to pa-
tient care and treatment decisions.
1H magnetic resonance spectroscopy (1H MRS) is a
powerful noninvasive tool for biochemically characterizing
normal and abnormal tissues [2, 3]. It has been used suc-
cessfully in the evaluation of brain diseases, particularly
with respect to brain tumors [4, 5]. It has also been used
to distinguish between malignant and benign diseases in
tissues such as the prostate [6], breast [7], and musculo-
skeletal system [8] . In the liver, 1H MRS not only has been
used to evaluate liver function and diffuse hepatic disease
such as liver steatosis, hepatitis and cirrhosis [9–14], but
also used to distinguish between benign and malignant
liver masses. Promising results have been obtained using
in vitro 1H MRS. Soper et al. [15] performed a diagnostic
correlation between 1H MRS and histopathology. They
found that normal liver and cirrhotic liver was distin-
guished from hepatocellular carcinoma (HCC) with accur-
acies of 100 and 98 % respectively, which was consistent
with Wang’s reaearch [16]. However, in vivo 1H MRS has
been reported in only a few studies to date, and limited
values were investigated. Kuo et al. [17] reported in vivo
1H MRS to be technically feasible, also at 3.0T, for the
evaluation of focal hepatic lesions and noted limitations in
distinguishing between normal liver, benign and malignant
tumors. Fischbach et al. [18] suggested only a tendency
towards increased choline-containing compound (CCC)
levels in the spectra of HCC lesions. Overall, malignant
entities did not show elevated CCC levels compared with
normal liver.
To our knowledge, all these studies have compared
CCC levels in tumors directly with those in normal livers.
However, the liver background is highly variable [19].
Therefore, we designed a new strategy, an analysis of
choline-containing compound ratio (ΔCCC), to eliminate
bio-variations. Thus, the purpose of our study was to pro-
spectively investigate ΔCCC using 1H MRS to distinguish
benign from primary malignant hepatic tumors, and to
compare the effects of 1H MRS on the diagnostic accuracy




From July 2009 to December 2010, 40 consecutive pa-
tients (mean age, 55.43 years ± 11.53 [standard deviation];
16 women) with 50 lesions were prospectively evaluated
using conventional MRI and 1H MRS. Inclusion criteria
for our study were as follows: (a) lesions are 1 cm or more
in diameter at axial images, (b) no other malignant tumor
history for 5 years before the diagnosis of hepatic lesion,
(c) first treatment is surgery without any preoperative
treatment. Exclusion Criteria for our study were as fol-
lows: (a) Patient with unresectable tumors, (b) patients
unwilling to undergo surgical treatment, (c) patients with
known liver metastases, and (d) contraindications to per-
form MRI.
Fifty control subjects (mean age, 50.16 years ± 14.48
[standard deviation]; 21 women) followed the same MRS
protocols. These control subjects had normal findings
from liver imaging (MRI, US or CT) and liver function
tests, and showed no clinical evidence of liver disease.
MR Imaging
Scanning was performed with a clinical whole-body 3.0-
T MR system (Signa HDxt; GE Healthcare, Chalfont St.
Giles, UK) with an 8-element phased array surface coil.
All subjects entered the magnet in supine feet-first pos-
ition. Conventional MR plain scan was performed in all
40 patients, of which 35 patients underwent dynamic
gadolinium-enhanced MRI. Point-Resolved Spectroscopy
(PRESS) 1H MRS was performed before enhanced MRI
(Table 1).
Conventional MR plain scans consisted of axial T1-
weighted gradient recalled echo in-phase and opposed-
phase sequences, an axial moderately T2-weighted fast
spin-echo sequence with fat suppression, and diffusion-
weighted imaging. Multiple phase dynamic enhancements
scan with liver acquisition with volume acceleration-
extended volume sequence as an optional sequence was
performed in 35 patients.
Axial, sagittal and coronal T2-weighted single-short fast
spin echo sequences were performed in each subject for
1H MRS localization. To maintain position consistency,
an expert in abdominal radiology positioned all MRS vox-
els. Six saturation bands were placed around the voxel
to diminish tissue contamination from the adjacent
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structures. In the patient group, one voxel was placed in
tumor and another was placed in tumor-free tissue, re-
spectively. The spectroscopic voxel size of tumor depends
on the size of the homogeneous part of the lesion. If the
lesion showed heterogeneous signal intensity, the voxel
should exclude hemorrhage, necrosis and calcification. In
the control group, a 2 × 2 × 2 cm3 voxel was placed in the
right lobe of live, avoiding large vessels, bile ducts and ad-
jacent structures. PRESS sequences were used to allow for
spatial localization of the 1H MRS voxel. The sequences
had a total of 64 acquisition times, with 2048 spectral data
points at a frequency of 2500Hz and a scanning time of
138 s. Data acquisition started when the water suppression
level was over 90 % and bandwidth was below 10 Hz after
auto shimming. A compression belt was used in each sub-
ject. Intermittent breath-hold was adopted during data ac-
quisition, starting at end-expiration. Based on monitoring
of breathing, data acquisition could be stopped sooner or
whenever the subject had to breathe again. The total ac-
quisition time for one spectrum in the breath-hold mode
amounted to 2 min 18 s on average, yielding a total meas-
urement time of 5 to 8 min including both acquisition and
resting time.
Reading of Conventional MR Images
Conventional MR images, including plain images and dy-
namic gadolinium-enhanced MR images, were allocated
to two radiologists, one of whom randomly chosen from a
junior panel (13 radiologists with less than 5 years of
gastrointestinal and hepatobiliary experience) and an ex-
perienced panel (14 radiologists with more than 10 years
of gastrointestinal and hepatobiliary experience), respect-
ively. The images were reviewed and graded blindly as ei-
ther 1, 2, 3, 4 or 5 according to the following guidelines:
grade 1 (definite benign lesion), grade 2 (suspected benign
lesion), grade 3 (uncertain lesion), grade 4 (suspected ma-
lignant lesion) and grade 5 (definite malignant lesion).
Analysis of MR Spectral Data
Analysis of raw spectral data was performed using com-
mercially available software (SAGE 2005; GE Healthcare).
For each patient, the data from the nearest channel was
chosen. Given the ability of data processing in SAGE, we
use same phase correction parameter in all frame rather
than phase correction frame by frame. Spectral postpro-
cessing included 5-Hz Gaussian filter, fast Fourier trans-
form, and phase and baseline correction. Fully automated
user-macros were developed for data post-processing.
A semi-quantification method was used, and internal
water (InW) was chosen as the reference metabolite to
minimize the systematic and shimming variance during
spectroscopy data acquisition. The peak areas at 3.2 ppm
in all cases were normalized according to the peak area of
the unsuppressed InW at 4.7 ppm. Using the choline-
containing compounds peak area (CCC-A) in the liver 1H
MR spectrum, we calculated the CCC-A ratio ΔCCC
using the following equation:
ΔCCC ¼ CCC−At–CCC−Atfð Þ=CCC−Atf
where CCC-At and CCC-Atf are the CCC-A of tumor
and tumor-free tissue in the same patient, respectively.
Statistical Analysis
The median and range of CCC-A values in the control
group, benign hepatic tumors and primary malignant hep-
atic tumors were described. One-way ANOVA was used
to compare the CCC-A among each group. The one-way
Table 1 Pulse sequence parameters for conventional magnetic resonance imaging and 1H magnetic resonance spectroscopy










T1-Weighted (In phase) GRE 275 2.3 7.0 1.0 288∗192 80 19 Breath hold
T1-Weighted (Out phase) GRE 275 5.8 7.0 1.0 288∗192 80 19 Breath hold
T2-Weighted (fat suppression) FSE – 102 7.0 1.0 288∗224 – – Respiratory-
triggered
Diffusion weighted EPI 3750 Min 7.0 1.0 128∗128 – 19 Breath hold




PRESS 1500 35 – – – – 138 Intermittent
breath hold
T2-weighted SSFSE 2300 60 7.0 1.0 288∗192 – 59 Intermittent
breath hold
Note: a, 35 of all 40 patients underwent this sequence
MRI magnetic resonance imaging, MRS magnetic resonance spectrograph, GRE gradient recalled echo, FSE fast spin echo, EPI echo planar imaging, LAVA-XV liver
acquisition with volume acceleration-extended volume, PRESS point-resolved spectroscopy, SSFSE single-short fast spin echo sequences, TR repetition time,
TE echo time
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T test was used to compare differences in the ΔCCC
between benign hepatic tumors and primary malignant
hepatic tumors. The diagnostic accuracies in hepatic ma-
lignant tumors of ΔCCC, conventional MRI read by junior
radiologist and conventional MRI read by experienced
radiologist were evaluated by receiver operating character-
istic (ROC) curve analyses. The effect of MRS on the diag-
nostic accuracy of liver-occupying lesions was compared
to junior and experienced radiologist. SPSS statistical soft-
ware version 17.0 (SPSS, Inc., an IBM Company, Chicago,
IL, USA) was used for all data analyses. Differences were
considered significant when two-sided P-values were less
than 0.05.
Results and discussion
Liver 1H MRS was acquired in 40 patients with 50 le-
sions and 50 control subjects. All individuals tolerated
the use of the compression belt and intermittent breath-
hold. A total of 140 spectra were acquired, among which
50 spectra were localized in liver lesions, 40 in tumor-
free tissue and the remaining 50 spectra were measured
in normal livers of control subjects. For the 40 patients,
1H MRS was performed on both tumor and tumor-free
tissue on the same day.
All patients were proved by surgical approach. Of 50
lesions, 15 had pathologically proven benign tumors (7
hemangiomas, 2 hydatidosises, 2 solitary necrotic nodules,
2 adenomas, 1 focal nodular hyperplasia and 1 angiomyo-
lipoma) and the remaining 35 lesions had pathologically
proven malignant tumors (26 HCC, 5 cholangiocarcino-
mas and 4 mixed hepatocellular and cholangiocarcino-
mas). The time-intervel between MRS/MRI scanning and
surgery is within 2 weeks.
Based on previous research, the peak area rather than
its amplitude is proportional to the amount of 1H nuclei
in the same chemical environment and, thus, the tissue
content of that chemical group or metabolite [20]. So
peak area was applied as an index to evaluate the quanti-
fication of CCC in liver. A CCC resonance was detected
at 3.2 ppm in all 35 malignant spectra, 9 of 15 benign
spectra and 49 of 50 control spectra (Fig. 1). The mean
± 1 standard deviation CCC-A for the control group, be-
nign tumor, and malignant tumors were 3.62 ± 2.92,
1.27 ± 1.68, and 4.16 ± 2.92, respectively (Fig. 2a). A sig-
nificant increase in mean CCC-A was observed in ma-
lignant tumors compared with benign tumors (ANOVA
planned contrast test, least significant difference [LSD],
P < 0.01), and no significant statistical difference was ob-
served between the control group and malignant tumors
(ANOVA planned contrast test, LSD, P = 0.38 and
Student-Newman-Keuls procedure, P = 0.48). The CCC-
A of normal liver in the control group and the patients
with liver lesions were 3.62 ± 2.92 and 2.83 ± 2.14, re-
spectively. No significant difference between the two
groups (t = −1.55, P = 0.124) was detected. The CCC-A
changes between tumor and tumor-free tissue in the
same case (Fig. 3) showed a decline among 15 benign
hepatic lesions (Fig. 4) and a significant increase among
35 malignant hepatic lesions (Fig. 5). The ΔCCC (Fig. 2b)
in the 35 malignant liver lesions was significantly higher
than that in the 15 benign liver lesions (Table 2).
The ROC curves for diagnosing primary malignant hep-
atic tumors with CCC-A and ΔCCC were plotted (Fig. 6).
The area under the ROC curves (AUC) with CCC-A and
ΔCCC was 0.64 (P = 0.03) and 0.97 (95 % confidence
interval: 0.94–1.00, P < 0.01), respectively. If −0.09 was
chosen as the cut-off value for diagnosing malignant tu-
mors with ΔCCC, the sensitivity and specificity for malig-
nant tumors using our criteria were 94.3 and 93.3 %,
respectively. Both of the AUCs for junior and experienced
radiologists were lower than the ΔCCC, while significantly
statistical difference was only observed in junior radiolo-
gists compared with ΔCCC (Table 3).
According to previously published liver 31P MRS stud-
ies [21–23], choline is one of the components of phos-
phatidylcholine, an essential element of phospholipids in
the cell membrane. Malignant tumors usually exhibit a
high proliferation of cells and are, therefore, associated
with increased metabolism of cell membrane compo-
nents. This biochemical background leads to an in-
creased presence of choline in viable cancer cells. On
the contrary, necrotic tumors have a lower cell density,
which leads to decreased choline concentration. Similar
results were shown in liver 1H MRS studies, both in
vitro and in vivo [15, 24], and were the foundation for
evaluating the therapeutic effectiveness of the response
of HCCs to locoregional therapy [25, 26]. In our study,
in order to localize more precisely, the spectroscopic
voxel size in the patient group ranged from 1.7 to 8 cm3
depending on the size of the homogeneous part of the
tumor. A decrease in the voxel of interest (VOI) may de-
crease the signal-to-noise ratio (SNR), on the basis of
previous research showing that <8 cm3 in VOI was in-
sufficient for the SNR or spectral quality when using the
PRESS technique in the liver [9]. Therefore, torso coil,
compression belt and intermittent breath-holding tech-
niques were used in our study to increase the sensitivity
and improve the resolution of the CCC peak [27]. Another
factor that may alter MR data is the choice of MR contrast
material [28, 29]. Although the impact of this approach re-
mains controversial, 1H MR spectra were performed be-
fore the administration of MR contrast material in all
patients. For balancing signal intensity and signal contrast,
an echo time (TE) of 35 ms was selected as the optimum
TE, consistent with previous research [30].
Qualification of the CCC concentration is essential
for characterizing differences between malignant and
benign tumors. The methods of quantifying liver CCC
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concentrations with 1H MRS include the use of an in-
ternal reference and an external phantom reference
[30]. Due to the high variability of liver background
[19, 30], an external reference was considered to be
more precise. However, this procedure, which requires
accurate calibration, is extensive and therefore imprac-
tical in the clinical setting. For this reason, we selected
water as the internal reference metabolite for measur-
ing CCC-A [31].
In our research, among the three groups, CCC-A con-
centrations in malignant tumors achieved the highest
values whereas benign tumors produced the lowest values,
consistent with the report of Kuo et al. [17]. A significant
difference in CCC levels between benign tumors and
Fig. 1 Localized magnetic resonance images and 1H magnetic resonance spectra in normal liver, benign tumor and malignant tumor. a Localized
magnetic resonance image shows location of the voxel of interest in normal liver. b 1H magnetic resonance spectrum shows a choline-containing
compound resonance at 3.2 ppm. c Localized magnetic resonance image shows location of the voxel of interest in a hemangioma. d 1H magnetic
resonance spectrum shows no significant choline-containing compound resonance at 3.2 ppm. e Localized magnetic resonance image shows location
of the voxel of interest in hepatocellular carcinoma. f 1H magnetic resonance spectrum shows a high choline-containing compound resonance
at 3.2 ppm
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Fig. 3 Graphs show changes of choline-containing compound between tumor and tumor-free tissue in each case. a Choline-containing compound
changes in benign hepatic tumor and tumor-free tissue. These data show a decrease tendency. b Choline-containing compound changes in malignant
hepatic tumor and tumor-free tissue. These data show an increase tendency
Fig. 2 Boxplots show choline-containing compound and choline-containing compound ratio for study groups. a NO statistically significant difference
of choline-containing compound exists between the control group and malignant group (P = 0.48). b Choline-containing compound ratio of
malignant group is significantly higher than that of benign group (P < 0.01)
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malignant tumors was observed in both our study and
other previous studies [17, 26]. In contrast, Fischbach et
al. [18] observed only a non-significant tendency for in-
creased CCC levels in malignant tumors in their study.
Several factors may have contributed to this difference.
First of all, different tumor types may have resulted in a
more variable CCC resonance. In a review by Podo on
phospholipid metabolism (including choline) in tumors
[32], it was concluded that the variation of different me-
tabolites within tumors may be due to different tumor cell
types, different phases of cell growth, and different tumor
grades. In our malignant tumor group, only primary ma-
lignant hepatic tumors were included while both primary
and secondary malignant hepatic tumors were observed in
the research of Fischbach et al. [18] It has also been illus-
trated that decreased CCC levels have been observed in
metastases of rectal and breast cancer [9], which may
reduce the difference in mean CCC levels between malig-
nant hepatic tumors and benign tumors. The selection of
VOI may be another factor. As we know, necrosis in ma-
lignant tumors leads to a decrease in choline concentra-
tion. In our study, the VOI strictly excluded hemorrhage,
necrosis and calcification in the patient group, and this
may have improved the detection of CCC in tumors.
Although we observed a significant increase in CCC-A
in primary malignant hepatic tumors, the ROC curve for
diagnosing malignant tumors presented only a moderate
value, with an AUC of 0.67. These results were highly
concordant with those from the research of Kuo et al.
[17], in which the AUC of 1H MRS in diagnosing pri-
mary malignant hepatic tumors was 0.71, with a sensitiv-
ity of 62 % and specificity of 69 %. However, in our
study, the ROC curve for ΔCCC achieved a high value
in diagnosing malignant tumors, with an AUC of 0.97.
Fig. 4 A 50-year-old female with a hemangioma in the left lobe of the liver. a Transverse gradient recalled echo-in phase T1-weighted magnetic
resonance image shows a hypointense lesion. b Transverse gradient recalled echo-out phase T1-weighted magnetic resonance image shows a
hyperintense lesion. c Transverse fast spin echo fat-saturated T2-weighted magnetic resonance image shows a hyperintense lesion. d Transverse
spin-echo echo-planner image at b value of 600 s/mm2 shows high-signal-intensity lesion. e-h Multiple phase dynamic enhancement scan with
liver acquisition with volume acceleration-extended volume magnetic resonance images show rapidly enhancing vessels at the periphery in the
arterial phase. The lesion was then “filled- in” centripetally. k Localized magnetic resonance image shows location of the voxel of interest in tumor
free tissue. m A choline-containing compound peak at 3.2 ppm was detected in tumor free tissue in 1H magnetic resonance spectrum, the
choline-containing compound-Atf = 0.63. n Localized magnetic resonance image shows location of the voxel of interest in tumor. o No choline-containing
compound peak was detected in tumor free tissue in 1H magnetic resonance spectrum, the choline-containing compound-At = 0
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Individual variance of liver CCC concentrations in our
population may have led to this result. Fischbach and
Bruhn [9] reported that a non-significant tendency for
increased CCC levels in the elderly population was ob-
served in their study with 3.0T 1H MRS. The observation
of no significant difference in CCC with in vivo 1H MRS
between the control group and malignant tumors [17, 30]
may prove the large variance in the population. In our
study, the ΔCCC was calculated via an equation, utilizing
the ratio of increased CCC levels in tumor tissue com-
pared with tumor-free tissue in the same patient; this ap-
proach eliminates any individual variation and greatly
improves the diagnostic value of 1H MRS in primary ma-
lignant hepatic tumors.
In our research, although both of the AUCs for con-
ventional MRI read by junior radiologist and conven-
tional MRI read by experienced radiologist were lower
than ΔCCC, significantly statistical difference was only
observed in conventional MRI read by junior radiologist
compared with ΔCCC, which means that the 1H MRS
with ΔCCC is more beneficial for junior radiologists in
distinguishing between malignant and benign hepatic
Table 2 Choline-containing compound value from 1H magnetic
resonance spectroscopy between benign lesion and malignant
lesion
Benign lesion (Mean ± 1
standard deviation)
Malignant lesion (Mean ± 1
standard deviation)
P value
CCC-At 1.27 ± 1.68 4.16 ± 2.92 <0.01
CCC-Atf 3.52 ± 2.19 2.53 ± 2.08 0.13
ΔCCC −0.62 ± 0.33 1.18 ± 1.41 0.02
Note: CCC choline containing compounds, CCC-At choline-containing compounds
peak area in tumor, CCC-Atf choline-containing compounds peak area in tumor
free tissue, ΔCCC choline-containing compounds peak area ratio
Fig. 5 A 67-year-old male with a hepatocellular carcinoma in the right lobe of the liver. a Transverse gradient recalled echo-in phase T1-weighted
magnetic resonance image shows an isointense tumor. b Transverse gradient recalled echo-out phase T1-weighted magnetic resonance image
shows an isointense lesion. c Transverse fast spin echo fat-saturated T2-weighted magnetic resonance image shows an isointense tumor with
center high-signal-intensity strip. d Transverse spin-echo echo-planner image at b value of 600 s/mm2 shows high-signal-intensity lesion.
e-h Multiple phase dynamic enhancement scan with liver acquisition with volume acceleration-extended volume magnetic resonance images show no
enhancement in the all phase. k Localized magnetic resonance image shows location of the voxel of interest in tumor free tissue. m A choline-containing
compound peak at 3.2 ppm was detected in tumor free tissue in 1H magnetic resonance spectrum, the choline-containing compound-Atf = 5.89.
n Localized magnetic resonance image shows location of the voxel of interest in tumor. o A choline-containing compound peak at 3.2 ppm
was detected in tumor in 1H magnetic resonance spectrum, the choline-containing compound-At = 6.66
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tumors. Conventional MR images, which have no quan-
titative indicators, are more rely on experience. However,
junior radiologists are lack of experience and do not
have profound understanding of the disease that may
lead to some misdiagnosis. ΔCCC as an automatic calcu-
lated index does not need too much experience, may be
a powerful assisted means in diagnosis of hepatic lesion
to junior radiologists.
Our study is not without some limitations. First, CCC-
A levels in tumor and tumor-free tissue were obtained
from two MR spectra respectively, which was time con-
suming and led to possible observational management
error. Hence, the development of multivoxel two- or
three-dimensional chemical shift MRS would be the best
method for future evaluation. Second, the scan time of
16 to 20 min was too long to be practical in clinical ap-
plication. Two scans and intermittent breath holding
were the main contributors. Future developments in
both software and hardware are necessary to shorten the
scanning procedure. Third, different tumor types should
be included in future studies: our study only evaluated
primary malignant tumors. Fourth, the patient popula-
tion in this study was relatively small, so further studies
with a larger number of patients are needed in order to
reach a more robust conclusion.
Conclusions
1H MRS with ΔCCC may be a useful strategy in diag-
nosing primary malignant hepatic tumors that, based on
the findings of our preliminary study, appears to be par-
ticularly beneficial for junior radiologists. The use of an
8-element phased array surface coil, compression belt,
intermittent breath-holding, and strict VOI selection, are
essential for accurate metabolite measurement. Further
development of MR techniques as well as additional
studies with a larger number of patients and different
tumor types are needed to confirm the usefulness of
ΔCCC in the clinical setting.
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